Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1162 - Comparison of HER2 related molecular expression and its significance for clinical outcomes between the primary and paired liver metastasis in advanced gastric cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

Hiroki Osumi

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

H. Osumi1, E. Shinozaki1, N. Yamamoto2, K. Chin1, M. Ogura1, D. Takahari1, T. Wakatsuki1, T. Ichimura1, I. Nakayama1, T. Matsushima1, A. Saiura3, T. Yamaguchi3, K. Yamaguchi1

Author affiliations

  • 1 Department Of Gastroenterology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Department Of Pathology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 3 Department Of Sugery, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
More

Resources

Abstract 1162

Background

Although clinical outcomes are improved with anti HER2 therapy for HER2 positive advanced gastric cancer (AGC), the relationship with HER2 related molecules and their significance for clinical outcomes are still unclear including the difference between the primary and paired liver metastasis in AGC.

Methods

A total of 58 AGC with liver metastasis were enrolled in this study from November 1995 to March 2009. We investigated HER2 protein expression by immunohistochemistry (IHC) using HercepTest (DAKO) in standard procedure and assessed according to Gastric Cancer Scoring System. HER2 positivity (3+) defined complete, basolateral or lateral membranous reactivity in > 10% of the cells. About the other molecular expressions (EGFR, c-MET, IGFR), positive expression was defined as 25% or more staining with intensity 2 or 3+. We also investigated the relationship between recurrence free survival (RFS), overall survival (OS) and HER2 related molecular expression in both primary and liver metastasis.

Results

The HER2 positivity (3+) rate of primary and liver metastasis were 11.5 (6/52) and 9.4% (5/53), respectively, and concordance rate between the primary and liver metastasis was 91.4% (53/58). The EGFR positivity rate of primary and liver metastasis were 1.7% (1/57) and 5.4% (3/55), respectively, and concordance rate between the primary and liver metastasis was 93.1% (54/58). The c-MET positivity rate of primary and liver metastasis were 44.8 (26/32) and 45% (18/40), respectively, and concordance rate between the primary and liver metastasis was 75.8% (44/58). The IGFR1 positivity rate of primary and liver metastasis were 45 (18/40) and 41.4% (17/41), respectively, and concordance rate between the primary and liver metastasis was 70.6% (41/58). Median RFS and OS were 7.3 months (6.2-11.8) and 34 months (16.2-41.7), respectively. There were no relationships between any HER2 related molecular expressions and RFS, OS in both primary and liver metastasis.

Conclusions

EGFR and HER2 were high concordance rate between the primary site and liver metastasis, respectively. There were no relationships between any HER2 related molecular expressions and clinical outcomes in this cohort.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.